Condition: Solid Tumor · Lymphoma · Sponsor: L & L Bio Co., Ltd., Ningbo, China
This is a Phase I study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, LB1410, is safe, tolerable and efficacious in participants with advanced solid tumors or lymphoma.
This description comes directly from the study's public registry record.
Yan Luan · +86-21-54152522 · luanyn2@lnlbio.com
Always discuss trial participation with your own doctor first.
| Shanghai Pulmonary Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05357651